Market Cap 530.17M
Revenue (ttm) 10.00M
Net Income (ttm) -29.47M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 28,075
Avg Vol 812,584
Day's Range N/A - N/A
Shares Out 140.26M
Stochastic %K 30%
Beta 0.88
Analysts Strong Sell
Price Target $6.80

Company Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteope...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 33 3023 7300
Address:
One Cavendish Place, 4th Floor, London, United Kingdom
ParallelPort
ParallelPort Apr. 24 at 1:09 AM
$MREO Just putting out something already known by most but i will put out there anyway for those that don't. Regardless of any news good bad or indifferent, .30 is pivotal to be held. If it breaks without an immidiate bounce there is no grounded resistance to catch it til .20. It held today and the last time it hit .30 it bounced back and held.
0 · Reply
TragicRain
TragicRain Apr. 23 at 12:00 PM
$MREO @ParallelPort - Do what you are doing - but no take the opposite view point. Because you say you are "trying to read the tea leaves" but its all positive - redo it, but take the negative view point.... you will see that both are possibilities and realities. We hope for positives, but we should expect this to be a tax write off -- that's the real gamble with all these bios.
1 · Reply
ParallelPort
ParallelPort Apr. 23 at 2:13 AM
$MREO Lets begin with what we know, this thing is pinned in algo hell right now. The only certain news ahead is the May 14th AGM where there is a key prop 10 vote to allow more shares. This actually doesn't matter at all as we know prop 10 will pass. The question is what if anything will be said of any relevance. If the vote passes and the PR remains silent, it’s interpreted as management clearing the deck for a desperate ATM offering just to keep the lights on through 2027. But on the other hand serious partners rarely sign term sheets with companies that don't have enough authorized shares to finalize the deal or issue warrants. In this case, Prop 10 is the "housekeeping" that must happen before they can announce a partner for the Alvelestat Phase 3. The fact is that the AATD-LD market (the lung disease Alvelestat targets) hasn't gone anywhere. The FDA has already blessed the 220-patient trial design. The longer they wait, the closer they get to the "End of Runway"
0 · Reply
ParallelPort
ParallelPort Apr. 23 at 2:11 AM
$MREO A few more tidbits here. We have now officially hit day 30 without Form 3s for Deepa Prasad, Jeremy Bender, and Justin Stephens. Board members don't usually stay "delinquent" for a month unless they are inside a blackout window for material news. This could potentially be what we are seeing on the tardiness. Filing those Form 3s on May 14th alongside a partnership would be the ultimate "institutional validation." I am only trying to read the tea leaves and find logical reasons and conclusions. If Type C news of the meeting being accepted happens before then it should blow right past .35 There is a literal "Supply Vacuum" betwee .35 and .38. Because the retail interest is currently zero, a single partnership headline or Type C news will likely cause the price to skip those levels entirely.
0 · Reply
davedtire
davedtire Apr. 22 at 6:15 PM
$MREO hey DSK are we even trading at cash value? Pathetic
0 · Reply
laaarsas
laaarsas Apr. 18 at 11:22 PM
$MREO Seems like I was right about this one. I should have gone for the shorting
0 · Reply
SebNo1234
SebNo1234 Apr. 18 at 11:03 AM
$MREO is above the 20-day line https://www.boerse.de/nachrichten/Mereo-Biopharma-Aktie-ueber-20-Tage-Linie/38273967
1 · Reply
ParallelPort
ParallelPort Apr. 16 at 1:25 PM
$MREO So hit .35 yesterday but turned out to be a liquidity grab for stop losses and panic selling for another institution to add. Let's see if it tries to break .35 again today or holds just below til options expire Friday.
0 · Reply
taneraydar
taneraydar Apr. 15 at 6:02 PM
$MREO watching closely! If volume hits i will get in with 20k
0 · Reply
Svetli_stock
Svetli_stock Apr. 15 at 5:46 PM
$MREO + 0.05 today
0 · Reply
Latest News on MREO
Mereo BioPharma Provides Update on Lead Clinical Programs

Jan 12, 2025, 11:05 AM EST - 1 year ago

Mereo BioPharma Provides Update on Lead Clinical Programs


ParallelPort
ParallelPort Apr. 24 at 1:09 AM
$MREO Just putting out something already known by most but i will put out there anyway for those that don't. Regardless of any news good bad or indifferent, .30 is pivotal to be held. If it breaks without an immidiate bounce there is no grounded resistance to catch it til .20. It held today and the last time it hit .30 it bounced back and held.
0 · Reply
TragicRain
TragicRain Apr. 23 at 12:00 PM
$MREO @ParallelPort - Do what you are doing - but no take the opposite view point. Because you say you are "trying to read the tea leaves" but its all positive - redo it, but take the negative view point.... you will see that both are possibilities and realities. We hope for positives, but we should expect this to be a tax write off -- that's the real gamble with all these bios.
1 · Reply
ParallelPort
ParallelPort Apr. 23 at 2:13 AM
$MREO Lets begin with what we know, this thing is pinned in algo hell right now. The only certain news ahead is the May 14th AGM where there is a key prop 10 vote to allow more shares. This actually doesn't matter at all as we know prop 10 will pass. The question is what if anything will be said of any relevance. If the vote passes and the PR remains silent, it’s interpreted as management clearing the deck for a desperate ATM offering just to keep the lights on through 2027. But on the other hand serious partners rarely sign term sheets with companies that don't have enough authorized shares to finalize the deal or issue warrants. In this case, Prop 10 is the "housekeeping" that must happen before they can announce a partner for the Alvelestat Phase 3. The fact is that the AATD-LD market (the lung disease Alvelestat targets) hasn't gone anywhere. The FDA has already blessed the 220-patient trial design. The longer they wait, the closer they get to the "End of Runway"
0 · Reply
ParallelPort
ParallelPort Apr. 23 at 2:11 AM
$MREO A few more tidbits here. We have now officially hit day 30 without Form 3s for Deepa Prasad, Jeremy Bender, and Justin Stephens. Board members don't usually stay "delinquent" for a month unless they are inside a blackout window for material news. This could potentially be what we are seeing on the tardiness. Filing those Form 3s on May 14th alongside a partnership would be the ultimate "institutional validation." I am only trying to read the tea leaves and find logical reasons and conclusions. If Type C news of the meeting being accepted happens before then it should blow right past .35 There is a literal "Supply Vacuum" betwee .35 and .38. Because the retail interest is currently zero, a single partnership headline or Type C news will likely cause the price to skip those levels entirely.
0 · Reply
davedtire
davedtire Apr. 22 at 6:15 PM
$MREO hey DSK are we even trading at cash value? Pathetic
0 · Reply
laaarsas
laaarsas Apr. 18 at 11:22 PM
$MREO Seems like I was right about this one. I should have gone for the shorting
0 · Reply
SebNo1234
SebNo1234 Apr. 18 at 11:03 AM
$MREO is above the 20-day line https://www.boerse.de/nachrichten/Mereo-Biopharma-Aktie-ueber-20-Tage-Linie/38273967
1 · Reply
ParallelPort
ParallelPort Apr. 16 at 1:25 PM
$MREO So hit .35 yesterday but turned out to be a liquidity grab for stop losses and panic selling for another institution to add. Let's see if it tries to break .35 again today or holds just below til options expire Friday.
0 · Reply
taneraydar
taneraydar Apr. 15 at 6:02 PM
$MREO watching closely! If volume hits i will get in with 20k
0 · Reply
Svetli_stock
Svetli_stock Apr. 15 at 5:46 PM
$MREO + 0.05 today
0 · Reply
polker9
polker9 Apr. 15 at 2:00 PM
0 · Reply
Bgirl_smirk
Bgirl_smirk Apr. 15 at 1:48 PM
$MREO starter
1 · Reply
Gunnar1
Gunnar1 Apr. 14 at 6:48 PM
$MREO I stepped in back yesterday. IMO it's undervalued at this point. Smaller position so far, will nibble here and there over the next time. Following the failure of the Phase 3 trial, setrusumab is likely already largely priced in as worthless, although there may still be a small chance of success for certain subgroups. The main asset is alvelestat, for which the company is actively seeking a partner and P3 planning is done. Vantictumab is a nice add-on, maybe some miletsone payments from āshibio are ahead. Cash run until mid 2027. Careful, small cap biotech = very high risk.
2 · Reply
ScottyDoesntKnowMeSon
ScottyDoesntKnowMeSon Apr. 14 at 2:29 PM
$MREO someone pump this for the longs. Have there been any updates whatsoever? I stopped paying attention
0 · Reply
Gall_t
Gall_t Apr. 13 at 2:58 PM
$MREO Mereo the next Maxeon ? 🧐
0 · Reply
Dracula88
Dracula88 Apr. 11 at 6:02 AM
$MREO will have an epic boom. 🫁👩🏻‍⚕️
2 · Reply
ParallelPort
ParallelPort Apr. 9 at 2:29 AM
$BMEA $MREO $EVMN My 2nd and last crosstag. BMEA- Since my post Thursday we are up from $1.48 to $1.99 and now at $1.76. My conviction analysis coming soon. MREO- Currently stale waiting to close back above .35 where .37 will come quickly after. Should happen by mid next week. EVMN- Since my post Thurday we are up from $23.00 to $27.00 There is a KOL Webinar scheduled for April 13 The company will detail why they believe MRGPRX2 inhibition is a viable pathway for preventing migraines. They are expected to announce plans to initiate a Phase 2b study in this indication during the third quarter of 2026. Presentations will cover the pathophysiology of migraine and how mast cells and peripheral sensory neurons (where the MRGPRX2 receptor is found) play a role in the disease. Investors expect a discussion on how this expansion affects the company's "shots on goal" and its positioning in the multibillion-dollar migraine treatment market.
0 · Reply
ParallelPort
ParallelPort Apr. 6 at 3:45 PM
$MREO Wanted to give a little more info on the increased volume and big block buys we saw Friday and this morning. Tomorrow, Tuesday, April 7, is the official Record Date for the AGM on May 14th. Because of T+1 settlement, today is the absolute final day an institution can buy shares and have them "settle" in time to vote on Proposal 10 (the Allotment Authority). To be officially recognized as a "Shareholder of Record" by the transfer agent on April 7, an institution must execute their buy order today, April 6. Shareholders holding at least 5% of the paid-up voting capital have the right to requisition a general meeting or require the company to circulate a statement to all shareholders. Certainly we will see this in future filings.
0 · Reply
ParallelPort
ParallelPort Apr. 5 at 9:07 PM
$MREO Not a lot going on right now but what we do have is positive. It looks as though we have some smaller institutions taking a little stake as we saw in the last few minutes of closing thursday. Also after monday all the lagal noise will be gone for awhile and we should see the price climb back between .37 and .39 maybe as early as end of week. Looking ahead there is more than likely nothing more to come until early to mid may with an announcement of a Type C meeting which should push us back to .44.
0 · Reply
Crivit
Crivit Apr. 2 at 8:00 PM
$MREO https://investorshub.advfn.com/p.php?pid=staticchart&s=mreo&p=0&t=17&showctype=1&width=800&vol=1&height=400&Vol=1
1 · Reply
ParallelPort
ParallelPort Apr. 2 at 2:47 PM
$MREO $BMEA $EVMN This will only be one of a couple multi tags before just singular. Starting this weekend i will be diving into BMEA and EVMN to go alongside MREO. What i post is neither bear nor bull, i try to keep it factual with just a few opinions. I know there are others on these boards who understand these companies trials and drugs better than i so i will leave that with them and hopefully elighten you all on other aspects. All three of these tickers i believe (my opinion) will at least +50% over the next 3 to 4 months, with shorter time frames for some, and higher percentages for others. I appreciate you all.
0 · Reply
ParallelPort
ParallelPort Mar. 30 at 5:28 PM
$MREO So i wanted to give a little update what is currently happening. There was a PRE 14A (Preliminary Proxy) filed on March 27 indicating the company is seeking shareholder authority at the May AGM to allot shares, providing them the legal mechanism to raise capital if a favorable window opens. Also the departure of Dr. Jenkins ties in. Dr. Jenkins has a reputation in the biotech world (as a former CEO and FDA Science Board member) for being highly focused on regulatory accountability. She wasn't a "legacy" director; she was a watchdog. Her departure suggests one less voice in the room that is strictly beholden to Rubric’s initial mandate for radical change. Proposal 10 (authority to allot shares) is the big one. This is the company asking for the power to issue more stock (dilute). Losing a director who was a staunch advocate for "shareholder value over dilution" right before this vote is a notable coincidence.
1 · Reply